INITIATION OF ANTIRETROVIRAL THERAPY IN HIV-INFECTION - A REVIEW OF INTERSTUDY CONSISTENCIES

被引:0
作者
VOLBERDING, PA
GRAHAM, NMH
机构
[1] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA
[2] JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1994年 / 7卷
关键词
ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; CLINICAL TRIALS; CD4(+) CELL COUNT;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A number of clinical trials have explored the optimal dosage for antiretroviral therapy and, in various ways, the optimal time, in terms of stage of human immunodeficiency virus (HIV) disease, at which treatment should begin. Some studies have shown that treatment with zidovudine results in a delay in progression to more advanced stages of HIV disease, and that the benefits are more durable among persons who started zidovudine with higher CD4(+) cell counts. Efficacy is preserved and toxicity is reduced when zidovudine is used at dosages lower than those originally recommended. The Concorde study found that administration of zidovudine to asymptomatic persons was associated with increases in CD4(+) cell counts and improvement in delaying disease progression at 55 weeks, but found no correlation between time of initiation of therapy and either longer-term delay in onset of symptomatic disease or ultimate survival. The analysis of these results, however, is complicated because of premature crossover of study participants from deferred treatment to immediate treatment. The consensus of the discussants of these studies is that antiretroviral treatment should be initiated by the time the CD4(+) cell count has fallen to 200-500 cells/mm(3). Although recognizing that, in general, viral infections call for treatment, the panelists were divided in their opinions about treatment of asymptomatic patients with CD4(+) cell counts >500/mm(3).
引用
收藏
页码:S12 / S23
页数:12
相关论文
共 19 条
[1]   ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER [J].
COOPER, DA ;
GATELL, JM ;
KROON, S ;
CLUMECK, N ;
MILLARD, J ;
GOEBEL, FD ;
BRUUN, JN ;
STINGL, G ;
MELVILLE, RL ;
GONZALEZLAHOZ, J ;
STEVENS, JW ;
FIDDIAN, AP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :297-303
[2]  
FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405
[3]   THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
HANSEN, N ;
COLLIER, AC ;
CAREY, JT ;
PARA, MF ;
HARDY, WD ;
DOLIN, R ;
POWDERLY, WG ;
ALLAN, JD ;
WONG, B ;
MERIGAN, TC ;
MCAULIFFE, VJ ;
HYSLOP, NE ;
RHAME, FS ;
BALFOUR, HH ;
SPECTOR, SA ;
VOLBERDING, P ;
PETTINELLI, C ;
ANDERSON, J .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) :727-737
[4]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[5]   A RANDOMIZED CONTROLLED TRIAL OF A REDUCED DAILY DOSE OF ZIDOVUDINE IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
FISCHL, MA ;
PARKER, CB ;
PETTINELLI, C ;
WULFSOHN, M ;
HIRSCH, MS ;
COLLIER, AC ;
ANTONISKIS, D ;
HO, M ;
RICHMAN, DD ;
FUCHS, E ;
MERIGAN, TC ;
REICHMAN, RC ;
GOLD, J ;
STEIGBIGEL, N ;
LEOUNG, GS ;
RASHEED, S ;
TSIATIS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1009-1014
[6]  
GRAHAM NMH, 1993, J ACQ IMMUN DEF SYND, V6, P1258
[7]   THE EFFECTS ON SURVIVAL OF EARLY TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
GRAHAM, NMH ;
ZEGER, SL ;
PARK, LP ;
VERMUND, SH ;
DETELS, R ;
RINALDO, CR ;
PHAIR, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) :1037-1042
[8]   EFFECT OF ZIDOVUDINE AND PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS ON PROGRESSION OF HIV-1 INFECTION TO AIDS [J].
GRAHAM, NMH ;
ZEGER, SL ;
PARK, LP ;
PHAIR, JP ;
DETELS, R ;
VERMUND, SH ;
HO, MT ;
SAAH, AJ .
LANCET, 1991, 338 (8762) :265-269
[9]  
GRAHAM NMH, 1994, LANCET, V343, P1355
[10]   A CONTROLLED TRIAL OF EARLY VERSUS LATE TREATMENT WITH ZIDOVUDINE IN SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - RESULTS OF THE VETERANS AFFAIRS COOPERATIVE STUDY [J].
HAMILTON, JD ;
HARTIGAN, PM ;
SIMBERKOFF, MS ;
DAY, PL ;
DIAMOND, GR ;
DICKINSON, GM ;
DRUSANO, GL ;
EGORIN, MJ ;
GEORGE, WL ;
GORDIN, FM ;
HAWKES, CA ;
JENSEN, PC ;
KLIMAS, NG ;
LABRIOLA, AM ;
LAHART, CJ ;
OBRIEN, WA ;
OSTER, CN ;
WEINHOLD, KJ ;
WRAY, NP ;
ZOLLAPAZNER, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (07) :437-443